Macquarie described Neuren Pharmaceuticals shares as a standout in the biotech industry and set a price target of $18.60 on ...

This ASX 300 stock is having a good session on Wednesday. Let's see why investors are bidding its shares higher ...

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor ...

Nvidia (NASDAQ: NVDA) investors have been very happy in recent years. Since 2020, shares have increased in value by roughly 1 ...

Analysts from Morgan Stanley believe the humanoid robot market could be worth $5 trillion by 2035. Musk believes Tesla could ...

Dylan Evans from Catapult Wealth has provided his views on two popular ASX REITs, Goodman Group (ASX: GMG) and BWP Trust (ASX ...

Aurizon Holdings has struck a new deal with materials giant BHP. Macquarie believes this is good news for Aurizon shares.

Citi currently has a buy rating and $2.70 price target on its shares. Another ASX dividend stock that has been given a buy ...

These 2 ASX growth shares could deliver big returns, in my opinion. Here’s why I’m excited about them right now.

The ASX dividend share is one of the leaders in the sector, in my opinion. It's expecting to pay a distribution per security ...

Bell Potter currently has a buy rating on the ASX tech share with a $122.50 price target. Based on its current share price of ...

The Vanguard Australian Shares Index ETF (ASX: VAS) is a very popular investment. But, there are other attractive ASX ETFs to ...